We're jokingly calling 2018 "Erowid's Year of Experience Report
Ketchup". The upcoming issue of Erowid Extracts (#30) is
dedicated to discussion and analysis of the Experience Vaults.
After over twenty years of collecting experience reports, we've been
tidying data, upgrading systems to better handle the amount of
information we now have, and making the types of changes that will
enable new features and improvements for readers in the near future.
Launched with a couple hundred reports in June 2000, and approaching
32,000 published reports today, the Experience Vaults have exceeded
the project's original scope and just keep growing.
1988: DEA administrative law Judge Francis Young rules, after
thorough hearings, that cannabis has clearly established medical use
and should be reclassified as a prescription drug. His recommendation
This issue announced the opening of five regional labs of the BNDD,
including one in San Francisco with Robert Sager as chief chemist.
Sager later became a good friend of Dr. Shulgin. Also, results of an
analysis of a "mescaline tablet" that contained LSD and caffeine.
Analysis of LSD tablets--barrels, "Peace Tablets", and two sizes of
orange "Sunshine"--with the first two containing 90-115 ug and the
latter 255-256 ug of LSD. Also, an error identified by Dr. Shulgin
about the structure of Ibogaine published in a 1968 issue, 35 drugs
analyzed by BNDD, and more.
EcstasyData is an Erowid project that conducts laboratory testing of
ecstasy tablets, research chemicals, and other drugs. We publish our
results online along with analyses from other drug checking programs.
The experience report crew is on track to reach an all-time high in
report publishing in 2018. In archiving news, scanning of Shulgin
materials is ongoing, volunteers are transcribing the next set of
Shulgin Pharmacology Notebook pages, and we're working on writing
abstracts for all items in the Stolaroff Collection.
Erowid is often mentioned in articles and books. Mentions may include
positive or critical reviews, as well as citations of Erowid content.
Penguin Press (May 2018)
In Michael Pollan's Acknowledgements: "For crucial research assistance
along the way [...] I'm deeply grateful to Earth and Fire, the
proprietors of Erowid, which is the single most important resource on
psychedelics there is." Awww...
Prescriber (Apr 2018)
"There is now a rich source of anecdotal reports that support
significant misuse of gabapentinoids both in the UK and
internationally, such as the user reports on the Erowid website."
A patent filed in 1959 on the use of MDMA as an appetite suppressant.
This is from Alexander Shulgin's file folders and is part of our
Shulgin Archiving project. Thanks to K Trout for his ongoing work
A few years ago, using a redacted version of their original database
and software, we made a complete copy of The Hive forums. Operational
from 1997-2004, The Hive was infamous for its explicit discussions of
chemistry, synthesis, and pharmacology of psychoactive chemicals. We
hear from readers that they forget how extensive the twisty mazes
inside Erowid are, and we want to remind people of some of the vast
and deep vaults you might not normally run across.
"At a certain point, the ceiling became a picture screen of sorts,
even rotating forward and becoming horizontal just like at a movie
theater. Simultaneously, I began to hear new sounds..."
"I convince myself that I am not going to get sick again and that I
need to go back to my room, unsure if I'm actually producing a
coherent conversation, which I am later told is quite erratic."
"I feel this is where there might be the critical point, as raised by
my partner, that perhaps such an experience is just "trapping" you in
your own bubble of beliefs if the feeling is of reinforcement..."
If you find Erowid a useful resource and are interested in supporting
its future development, please consider donating or becoming a member.
Donations to Erowid Center are tax-deductible in the United States.
- To UNSUBSCRIBE - send an empty email to: firstname.lastname@example.org
- To SUBSCRIBE - send an empty email to: email@example.com